Local and systemic responses against ricin toxin promoted by toxoid or peptide vaccines alone or in liposomal formulations

Vaccine

Volumn 16, Issue 5, 1998, Pages 530-535

  Griffiths, Gareth D ^a   Bailey, Stephen C ^a   Hambrook, Joy L ^a   Keyte, Martin P ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

A chain; Liposome; Protection; Ricin; Toxoid; Vaccine

Indexed keywords

LIPOSOME; RICIN; RICIN ANTIBODY; TOXOID; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; LUNG INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT; RICINUS COMMUNIS; VACCINATION;

EID: 0032033575     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)80007-2     Document Type: Article

References (29)

1. 1 Olsnes, S. and Pihl, A. Toxic lectins and related proteins. In: Molecular Action of Toxins and Viruses (Eds Conen, P. and Van Heyningen, S.). Elsevier, Amsterdam, 1982, pp. 51-105
2. 2 Griffiths, G.D., Rice, P., Allenby, A.C., Bailey, S.C. and Upshall, D.G. Inhalation toxicology and histopathology of ricin and abrin toxins. Inhalation Toxicol. 1995, 7, 269-288.
3. 3 Crompton, R. and Gall, D. Death in a pellet. Medico-legal J. 1980, 48, 51-62.
4. 4 Knight, B. Ricin - a potent homicidal poison. Br. Med. J. 1979, 3 Feb., 350-351
5. 5 UN. Convention on the Prohibition of the Development, Production, Stockpiling and Use of Chemical Weapons and on Their Destruction. United Nations, 1993
6. 6 Stirpe, F. and Barbieri, L. Ribosome-inactivating proteins up to date. FEBS 1986, 195, 1-8.
7. 7 Stirpe, F., Barbieri, L., Battelli, M.G., Soria, M. and Lappi, D. Ribosome-inactivating proteins from plants: present status and future prospects. Biotechnology 1992, 10, 405-412.
8. 8 Barbieri, L., Battelli, M.G. and Stirpe, F. Ribosome-inactivating proteins from plants. Biochem. Biophys. Acta 1993, 1154, 237-282.
9. 9 Olsnes, S., Refsnes, K. and Pihl, A. Mechanism of action of the toxic lectins abrin and ricin. Nature 1974, 249, 627-631.
10. 10 Griffiths, G.D., Lindsay, C.D. and Upshall, D.G. Examination of the toxicity of several protein toxins of plant origin using bovine pulmonary endothelial cells. Toxicology 1994, 90, 11-27.
11. 11 Griffiths, G.D., Lindsay, C.D., Allenby, A.C., Bailey, S.C., Scawin, J.W., Rice, P. and Upshall, D.G. Protection against inhalation toxicity of ricin and abrin by immunisation. Human Exper. Toxicol. 1995, 14, (2), 155-164.
12. 12 Gupta, R.K. and Siber, G.R. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 1995, 13, 1263-1276.
13. 13 Fortin, A. and Therein, H.-M. Mechanism of liposome adjuvanticity: an in vivo approach. Immunobiology 1993, 188, 316-322.
14. 14 Griffiths, G. D., Bailey, S. C., Hambrook, J. L., Keyte, M., Jayasekera, P., Miles, J. and Williamson, E. D. Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin. Accepted for publication in Vaccine (May 1997)
15. 15 Pastan, I., Chaudhary, V. and Fitzgerald, D.J. Recombinant toxins as novel therapeutic agents. Ann. Rev. Biochem. 1992, 61, 331-354.
16. 16 Strocchi, P., Barbieri, L. and Stirpe, F. Immunological properties of ribosome-inactivating proteins and a saporin immunotoxin. J. Immunol. Meth. 1992, 155, 57-63.
17. 17 Harlow, E. and Lane, D. (Eds). Antibodies, A Laboratory Manual. Cold Spring Harbor Laboratory, USA, 1988
18. 18 Holmgren, J., Brantzaeg, P. and Capron, A, et al. Concerted efforts in the field of mucosal immunology; Reports of the Expert Panel VI. European Commission Cost/STD Initiative. Vaccine 1996, 14, 644-664.
19. 19 Gregoriadis, G. Liposomes as immunological adjuvants: approaches to immunopotentiation including ligand-mediated targeting to macrophages. 41st Forum in Immunology. Res. Immunol. 1992, 143, 177-256.
20. 20 Szoka, F.C. The macrophage as the principal antigen-presenting cell for liposome-encapsulated antigen. 41st Forum in Immunology. Res. Immunol 1992, 143, 186-188.
21. 21 Alving, C.R. Liposomes as carriers of antigens and adjuvants. J. Immunol. Meth. 1991, 140, 1-13.
22. 22 de Haan, A., Geerligs, H.J., Huchshorn, J.P., van scharrenburg, A.M. and Wilschut, J. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 1995, 13, 155-162.
23. 23 de Haan, A., Tomee, J.F.C., Huchshorn, J.P. and Wilschut, J. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine 1995, 13, 1320-1324.
24. 24 McGhee, J.R., Mestecky, J., Dertzbaugh, M.T., Eldridge, J.H., Hirasawa, M. and Kiyono, K. The mucosal immune system: from fundamental concept to vaccine development. Vaccine 1992, 10, 75-87.
25. 25 Williamson, E. D., Eley, S. M., Stagg, A. J., Green, M., Russell, P. and Titball, R. W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunised animals against pneumonic plague. Submitted to Vaccine (Dec. 1996)
26. 26 Thorpe, S.C., Murdoch, R.D. and Kemeny, D.M. Regulation of IgE in the rat. I. The effect of the castor bean toxin, ricin, on IgE and IgG responses. Immunol. 1989, 68, 307-311.
27. 27 Cooper, P. D. The selective induction of different immune responses by vaccine adjuvants. In: Strategies in Vaccine Design (Ed. Ada, G. L.). R. G. Landes Company, 1994, pp. 125-158.
28. 28 Gizurarson, S., Jonsdottir, V.M. and Heron, I. Intranasal administration of diphtheria toxoid. Selecting antibody isotypes using formulations having various lipophilic characteristics. Vaccine 1995, 13, 617-621.
29. 29 Cryz, S., Davis, S.S. and Gregoriadis, G. et al. Vaccine delivery systems. Report of the Expert Panel, VII European Commission Cost/STD Initiative. Vaccine 1996, 14, 665-690.